Skip to content

Novel CYP26A1-Selective Inhibitors

The inhibitors enhance retinoic acid treatment efficacy and safety

Published: 31st August 2022
Novel CYP26A1-Selective Inhibitors
Anusorn, https://stock.adobe.com/uk/500730638, stock.adobe.com
Patents
  • Granted US Patents 10,874,634 and 11,364,220, “Compounds and methods for inhibiting CYP26 enzymes”
  • Pending Canadian Patent Application Serial No. 3,047,433, “Compounds and Methods for Inhibiting Cyp26 Enzymes”
IP Status
  • Patented
Seeking
  • Development partner
  • Commercial partner
  • Licensing
  • Seeking investment